Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies

BACKGROUND: In the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study of patients with relapsing-remitting multiple sclerosis, treatment with cladribine tablets 3.5 mg/kg (CladT) significantly reduced the annualised relapse rate (ARR) versus placebo; this effect was sustained in C...

Descripción completa

Detalles Bibliográficos
Autores principales: De Stefano, Nicola, Sormani, Maria Pia, Giovannoni, Gavin, Rammohan, Kottil, Leist, Thomas, Coyle, Patricia K, Dangond, Fernando, Keller, Birgit, Alexandri, Nektaria, Galazka, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688984/
https://www.ncbi.nlm.nih.gov/pubmed/33969750
http://dx.doi.org/10.1177/13524585211010294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688984/
https://www.ncbi.nlm.nih.gov/pubmed/33969750
http://dx.doi.org/10.1177/13524585211010294

Ejemplares similares